MDxHealth disclosed the results of the Oxford ProMPT study, a six‑year follow‑up of 409 men with localized or locally advanced prostate cancer, on March 16, 2026. The study was presented at the 41st Annual European Association of Urology Congress, which ran from March 13 to 16, 2026. GPS mdx, a 17‑gene expression assay performed on prostate biopsy tissue, demonstrated that it can identify patients with biologically indolent disease even among those with higher clinical risk factors.
In the active‑surveillance cohort, 92% of patients remained free from treatment failure, while those who underwent radical prostatectomy or radiotherapy achieved up to 100% freedom from failure. These outcomes match those seen in low‑risk patients and reinforce GPS mdx’s role as a decision‑support tool that can guide clinicians toward personalized treatment plans, potentially reducing overtreatment and improving patient outcomes.
MDxHealth’s CEO, Michael K. McGarrity, said, "This presentation represents the first major milestone in our research collaboration with the University of Oxford and is an important step forward as we advance the GPS‑ProtecT study together." Professor Freddie Hamdy of Oxford added, "These results demonstrated that genomic insights from the GPS mdx test can identify patients with favorable tumor biology even among clinically higher‑risk groups, helping clinicians better tailor treatment strategies and potentially avoid overtreatment."
The company is expanding GPS mdx adoption across multiple therapeutic pathways, a strategy that could drive additional revenue growth. MDxHealth has already launched GPS mdx testing in the UK ProtecT trial, announced on January 6, 2026, and is working to integrate the ExoDx acquisition into its portfolio. While the company has reported net losses in recent quarters, it has shown consistent revenue growth, with Q1 2025 revenue at $24.3 million and Q4 2025 revenue at $29.5 million, and it has guided 2026 revenue growth to 27–30%.
The Oxford ProMPT study’s findings provide robust clinical evidence that GPS mdx can stratify prostate cancer patients more accurately than traditional clinical risk factors alone. By enabling more precise treatment decisions, the test supports MDxHealth’s broader goal of improving patient outcomes while potentially reducing the costs associated with overtreatment. The study’s results are expected to strengthen the company’s competitive position in the precision diagnostics market and may accelerate the adoption of GPS mdx in both the United States and the United Kingdom.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.